Supercharged immune cells take aim at childhood cancer

NCT ID NCT03294954

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This study tests a new treatment for children with neuroblastoma that has come back or not responded to standard therapy. Researchers take the child's own immune cells (called NKT cells), add a special receptor to help them recognize and attack the cancer, and also add a molecule to help them last longer. The cells are given back along with a drug called etanercept, which may slow tumor growth. The goal is to find the safest and most effective dose and see if the treatment shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NEUROBLASTOMA NEUROBLASTOMA